Background and aims:Several bile acids-based monotherapies have been developed for non-alcoholic steatohepatitis(NASH)treatment but clinical trial findings suggest that they do not satisfactorily improve NASH and live...
This work was supported by the National Natural Science Foundation of China(grants 81730024 and 81825004);the National Key Research and Development Program of China(2018YFA0800601);the Scientific and Technological Research Project of Xinjiang Production and Construction Corps(grants 2018AB018 and 2021AB028);the Tianjin Research Innovation Project for Postgraduate Students(2021YJSB259).
Bile acid(BA)homeostasis is regulated by the extensive cross-talk between liver and intestine.Many bile-acid-activated signaling pathways have become attractive therapeutic targets for the treatment of metabolic disor...
The manipulation of bile acid (BA) homeostasis by blocking the ileal apical Na+-dependent bile salt transporter (ASBT/SLC10A2) may have therapeutic effects in nonalcoholic fatty liver disease. We developed a novel ASB...
supported by the National Natural Science Foundation of China(Nos.81473098 and 81473099);Hebei Provincial Key Research Project of Medical Science(Nos.ZD20140027 and 20150588)
The apical sodium-dependent bile acid transporter(ASBT) is the main transporter to promote re-absorption of bile acids from the intestinal tract into the enterohepatic circulation.Inhibition of ASBT could increase the...